Peripheral arterial disease: Recognition and medical management

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 7, 2006, Pages 621-638

  AlMahameed, Amjad ^a,b  

^a Vascular Medicine Research   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PENTOXIFYLLINE; RAMIPRIL; SIMVASTATIN;

ANGIOGENESIS; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DYSLIPIDEMIA; EXERCISE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LEG ULCER; LIMB AMPUTATION; LIMB ISCHEMIA; META ANALYSIS; MORBIDITY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVASCULARIZATION; RISK FACTOR; SMOKING CESSATION; SYMPTOM; SYSTEMATIC REVIEW;

HUMANS; HYPERTENSION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK FACTORS; SMOKING CESSATION;

EID: 33746080431     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.7.621     Document Type: Article

References (69)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743.
2. Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol 2002; 13:7-11.
3. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286:1599-1606.
4. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2:221-226.
5. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995, 274:975-980.
6. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-1324.
7. McDermott MM, Kerwin DR, Liu K. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice. J Gen Intern Med 2001; 16:384-390.
8. Criqui MH, Brower D, Fronek A, et al. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease. An analysis of risk factors. Am J Epidemiol 1989; 129:1110-1119.
9. AlMahameed A, Bartholomew JR. Peripheral arterial disease. In: Topol EJ, editor. Textbook of Cardiovascular Medicine. In press.
10. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995; 91:1472-1479.
11. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88:837-845.
12. Murabito JM, D'Agostino RB, Silbershatz H, et al. intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997; 96:44-49.
13. Kannel WB, Shurtleff D. The Framingham Study. Cigarettes and the development of intermittent claudication. Geriatrics 1973;28:61-68.
14. Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004, 109:2613-2616.
15. Ridker PM, Stampfer MJ, Rifal N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
16. Pradhan AD, Rifai N. Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106:820-825.
17. Falcone RA, Hirsch AT, Regensteiner JG, et al. Peripheral arterial disease rehabilitation: a review. J Cardiopulmon Rehab 2003; 23:170-175.
18. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. Vasc Med 2000, 5:55-59.
19. Hiatt WR, Nawaz D, Regenstelner JG, et al. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopul Rehabil 1988, 8:525-532.
20. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002; 136:873-883.
21. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292:453-461.
22. Boyd AM. The natural course of arteriosclerosis of the lower extremities. Proc R Soc Med 1962; 55:591-593.
23. Imparato AM, Kim GE, Davidson T, et al. Intermittent claudication: its natural course. Surgery 1975; 78:795-799.
24. McAllister FF. The fate of patients with intermittent claudication: managed nonoperatively. Am J Surg 1976; 132:593-595.
25. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94:3026-3049.
26. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286:1599-1606.
27. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199:223-233.
28. Nikolsky E, Mehran R, Dangas GD, et al. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. Am J Cardiol 2004, 93:1536-1539.
29. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19:538-545.
30. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
31. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic inter-Society Consensus (TASC). J Vasc Surg 2000; 31:S1-S296.
32. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517-538.
33. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-386.
34. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87:119-128.
35. Edwards JE, Taylor LM Jr. Porter JM. Treatment of failed lower extremity bypass grafts with new autogenous vein bypass grafting. J Vasc Surg 1990; 11:136-144.
36. Ingolfsson IO, Sigurdsson G, Sigvaldason H, et al. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol - The Reykjavik Study. J Clin Epidemiol 1994; 47:1237-1243.
37. Dagenais GR, Maurice S, Robitaille NM, et al. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med 1991; 14:93-100.
38. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221:253-260.
39. McGrath MA, Graham AR, Hill DA, et al. The natural history of chronic leg ischemia. World J Surg 1983; 7:314-318.
40. Lang GC, Papacosta O, Whincup P, et al. Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis 2000; 152:167-174.
41. Hobbs SD, Bradbury AW. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur J Vasc Endovasc Surg 2003; 26:341-347.
42. Willigendaell EM, Teljink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42:67-74.
43. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983; 1:217-219.
44. Anderson JE, Jorenby DE, Scott WJ, et al. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121:932-941.
45. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevertion of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of deat, myocordial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
48. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment panel III guidelines. Circulation 2004; 110:227-239.
49. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
50. McDermott MM, Gurainik JM, Greenland P et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107:757-761.
51. Mondillo S. Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114:359-364.
52. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481-1486.
53. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-1776.
54. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001; 87:1284-1286.
55. Yusuf S, Sleight P, Pogue J, et al. Effects of an anglotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engi J Med 2000, 342:145-153.
56. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25:17-24.
57. Chobanian AV, Balaris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
58. Olin JW. Hypertension and peripheral arterial disease. Vasc Med 2005; 10:241-246.
59. Thomas F, Rudnichi A, Bacri AM, Bean K, Gulze L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37:1256-1261.
60. Lee AJ, MacGregor AS, Hau CM, et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol 1999; 105:648-654.
61. Wilson PWF, Kannel WB. Epidemiology of hyperglycemia and atherosclerosis. In: Ruderman N, Williamson J, Brownlee M, editors. Hyperglycemia, Diabetes, and Vascular Disease. New York: Oxford University Press, 1992:21.
62. Jonason T, Ringqvist I. Diabetes mellitus and intermittent claudication. Relation between peripheral vascular complications and location of the occlusive atherosclerosis in the legs. Acta Med Scand 1985; 218:217-221.
63. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159:337-345.
64. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274:975-980.
65. Leng GC, Fowler O, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;(2):CD000990.
66. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997; 48:291-300.
67. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159:2041-2050.
68. Hood SC, Maher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155:1053-1059.
69. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). www.acc.org/clinical/guidelines/pad/index.pdf.